RTW

LENZ Therapeutics and Graphite Bio Announce Merger Agreement

Retrieved on: 
Wednesday, November 15, 2023
Health, Health Technology, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, NDA, Graphite, RTW, Therapy, PIPE, Multimedia, Presbyopia, Investment, FDA, New Drug Application, Pharmaceutical industry

LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Key Points: 
  • LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
  • Graphite Bio is expected to contribute $115 million to the combined entity and expects to pay a dividend to Graphite Bio shareholders of approximately $60 million at the close of the transaction.
  • “I am pleased to announce our merger with Graphite Bio, allowing us to create a publicly traded company focused on the advancement of LENZ’s lead programs, LNZ100 and LNZ101 for the treatment of presbyopia.
  • “LENZ Therapeutics is strongly positioned with Phase 3 lead program, addressing a very large target market with near-term, high potential, value-inflecting milestones and a well-credentialed management team to lead the combined company.”

UroGen Pharma Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Pharmaceutical, Health, Oncology, NDA, Medicine, Webcast, Rated R, NMIBC, RTW, Chemistry, Risk, TURBT, Patient, Investment, Probability, Research, Carcinoma, LG, FDA, Mitomycins, Conference, ATLAS, Software, Death, CMC, Nephrectomy, Growth, CRR, Recurrence, URS, Role, Pharmaceutical industry, Medical imaging, Dietary supplement, Video game, Agency

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent developments.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent developments.
  • “During the third quarter, UroGen achieved several notable milestones, including announcement of unprecedented positive results from our ENVISION and ATLAS Phase 3 trials of UGN-102 in LG-IR-NMIBC,” said Liz Barrett, President, and Chief Executive Officer of UroGen.
  • Activated sites on November 1, 2023 were 1,088, compared to 1,058 on August 1, 2023, while repeat accounts on November 1, 2023 were 296, compared to 267 on August 1, 2023.
  • Third Quarter 2023 Financial Results:
    JELMYTO Revenue: UroGen reported net product revenue of JELMYTO for the third quarter 2023 of $20.9 million, compared to $16.1 million in the third quarter of 2022.

Acacia Research Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Professional Services, Business, Finance, Webcast, Acquisition, Senior, RTW, Rights, Interim, Intellectual property, Investment, Exercise, Book value, Common stock, LSE, Printronix, United, Note, GAAP, Port and starboard, Security (finance), Video game, Cryptocurrency, Series, Acacia

With the right processes in place and a growing number of opportunities, I am confident that 2024 will be a year of tangible progress.”

Key Points: 
  • With the right processes in place and a growing number of opportunities, I am confident that 2024 will be a year of tangible progress.”
    Third Quarter 2023 Financial Summary:
    Total revenues were $10.1 million, compared to $15.9 million in the same quarter last year.
  • Printronix generated $8.3 million in revenue during the quarter, compared to $9.6 million in the same quarter last year.
  • The Intellectual Property business generated $1.8 million in licensing and other revenue during the quarter, compared to $6.3 million in the same quarter last year.
  • Acacia owns 64% of MalinJ1, which results in a 26% ownership stake in Viamet Pharmaceuticals, Inc. for Acacia.

REVOLVE GROUP ANNOUNCES REVOLVE + FWRD ACTIVATIONS IN ASPEN FOR WINTER 2023 / 2024

Retrieved on: 
Thursday, December 14, 2023
NYSE, Bolt, RTW, Millennials, Generation, Heart, Fashion, Snow, Partnership, Generation Z, Jewellery, Retail, Nightclub, Aspen, ASPEN

ASPEN, Colo., Dec. 14, 2023 /PRNewswire/ -- REVOLVE Group, Inc. (NYSE: RVLV), the next-generation fashion retailer for Millennial and Generation Z consumers, announces its pop-up shop and immersive retail experience, nestled in the heart of Aspen, Colorado. This limited-time pop-up will showcase a carefully curated selection of unique collections from both REVOLVE and FWRD, inviting customers to engage with their favorite brands in real life and shop a highly curated assortment of styles from their winter collections. For the first time, customers will have the unique opportunity to explore and shop from both sites in one store.

Key Points: 
  • REVOLVE Group's strategic activation in Aspen is driven by the unparalleled appeal of this iconic winter destination.
  • The Aspen Pop-Up is meticulously curated, featuring a selection of distinguished brands from REVOLVE and FWRD, ranging from emerging designers to cold-weather essentials, menswear, beauty products, and accessories.
  • The REVOLVE + FWRD Pop-Up will be open December 15, 2023 until March 17, 2024.
  • "We're thrilled to announce our presence in Aspen this winter with the launch of our REVOLVE and FWRD Pop-Up, an immersive and vibrant retail destination.

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

Retrieved on: 
Tuesday, November 7, 2023
NAV, Investment, Acquisition, Initial public offering, RTW, Security (finance)

On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal.

Key Points: 
  • On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal.
  • It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO’s NAV by c $550m (c 63%).
  • Arix’s shareholders would receive new RTWBIO shares at an implied c 46% premium to the level before Arix announced a strategic review.
  • Meanwhile, RTWBIO’s management team anticipates that the deal would be single-digit accretive to the company’s NAV per share at completion.

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work

Retrieved on: 
Monday, November 6, 2023
TBI, Insurance, HTC, Headache, Gait, Occupation, Health, Disability, Tongue, Pacific Blue Cross, PBC, Quality of life, Rehabilitation, Pons, HSDT, Patient, Traumatic brain injury, RTW, Nursing, Health care

NEWTOWN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the publication of a white paper demonstrating that rehabilitative treatment with the Portable Neuromodulation Stimulator (“PoNS®”) can drastically improve return-to-work (“RTW”) outcomes for patients suffering from TBI. The report, entitled “Evaluating the Real-World Impact of PoNS Therapy™ on Return-to-Work Outcomes in Individuals on Long-Term Disability due to Traumatic Brain Injury,” was co-sponsored by Pacific Blue Cross (“PBC”) and HealthTech Connex (“HTC”), and performed at the Surrey Neuroplasticity Clinic. The Centre for Neurology Studies collected and analyzed the data and released it in a white paper, which can be found on HTC’s website.

Key Points: 
  • The Centre for Neurology Studies collected and analyzed the data and released it in a white paper, which can be found on HTC’s website .
  • However, its efficacy varies widely, and many patients reach plateaus over time or even lose some function regained through rehabilitation.
  • “In addition to significant improvements in balance and gait disability, PoNS Therapy helped with headache, cognitive, and mental health symptoms.
  • We are pleased to have contributed to this impactful study with our innovative PoNS Therapy and proud of the role this treatment plays in improving the health of TBI patients.”

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

Retrieved on: 
Monday, October 30, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Citadel, LP, Sale, Security (finance), IND, Rare, Paradigm, Investment, Genzyme, LDL, Clinical trial, TED, Immunoglobulin G, Stifel, Autoimmunity, Safety, Therapy, Exchange, Patient, RTW, Colorado College, Pharmaceutical industry, Management, Neonatal Fc receptor, Boston College, Viridian

Viridian also disclosed a preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases.

Key Points: 
  • Viridian also disclosed a preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases.
  • He most recently served as President, Chief Financial and Operating Officer of Magenta Therapeutics.
  • Proceeds will be used to fund pipeline programs, including the FcRn portfolio, and for general corporate purposes and working capital.
  • Jefferies, Evercore ISI, and Stifel are acting as lead placement agents for the private placement financing.

Playground - The Next Evolution in Sexual Wellness - Redefines Pleasure with New Mood Maker Intimacy Oil

Retrieved on: 
Tuesday, October 24, 2023
Maker, Female, Cordyceps, System, Fleur du Mal, Paraben, PEGS, Entrepreneurship, Condom, Propylene glycol, Vulva, Lingzhi (mushroom), Meadowfoam seed oil, Partnership, Arousal, SAN, Pleasure, Mineral oil, Withania somnifera, Hormone, Woman, Sulfate, Call-progress tone, Human, RTW, Playground, Brassica oleracea, Birth control, Gluten

SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Playground, the pioneering sexual wellness brand co-founded by Christina Aguilera, is thrilled to unveil its latest innovation, Mood Maker, a clean, pH-balanced intimacy oil that revolutionizes the way we experience pleasure. Crafted with a vagina-safe formula, Mood Maker uses botanical aphrodisiacs to promote arousal and support a healthy libido. The product marks Playground's first release following its inaugural line of clinically tested,vagina-healthy personal lubricants. Within this new product category, Playground will continue to create good-for-you pleasure essentials intentionally designed for women.

Key Points: 
  • SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Playground , the pioneering sexual wellness brand co-founded by Christina Aguilera, is thrilled to unveil its latest innovation, Mood Maker, a clean, pH-balanced intimacy oil that revolutionizes the way we experience pleasure.
  • Crafted with a vagina-safe formula, Mood Maker uses botanical aphrodisiacs to promote arousal and support a healthy libido.
  • Within this new product category, Playground will continue to create good-for-you pleasure essentials intentionally designed for women.
  • Prioritizing vaginal health over topical irritants, Mood Maker is a botanical masterpiece designed to enhance pleasure, kindle desire, and support a healthy libido.

New York City Science and Education Nonprofits Launch Program to Inspire Bronx Youth to Pursue Careers in STEM

Retrieved on: 
Friday, October 20, 2023
Philanthropy, Consumer, Other Education, Teens, Primary, Secondary, Education, Foundation, Children, Science, Biotechnology, Other Science, Health, Breakfast, Data analysis, RTW, Life, HPAC, Student, Lawrence Hall of Science, MSW, Organization, Doctor of Philosophy, Investment, Hall, Mentorship, Nonprofit organization, Drug development, Learning, BioBus, Medicine, Weill Cornell Medicine, Tutoring, Management, Nursing, STEM, Black

The BioQuest program seeks to close this gap and inspire underrepresented students to pursue pathways and careers in science, biotech, and medicine.

Key Points: 
  • The BioQuest program seeks to close this gap and inspire underrepresented students to pursue pathways and careers in science, biotech, and medicine.
  • Additionally, BioBus will bring its fully equipped mobile lab to the South Bronx for interactive activities with mentors and students.
  • Students also connected with mentors, each of whom gave individualized insights into potential careers that connect with students’ interests and skills.
  • “We’re excited to leverage our collective expertise to get students from the South Bronx excited to explore careers in science, biotechnology, and medicine.

Global Genes' RARE-X Names Winners to the Xcelerate RARE Open Science Data Challenge

Retrieved on: 
Wednesday, September 20, 2023
Sage Bionetworks, Analytics, Roche, St. Jude Children's Research Hospital, Xcelerator, Research, Rare, Scientific programming language, Global Genes, Patent, Machine learning, SAN, Data, Algorithm, RTW, Gene, Challenge, Diagnosis, Hospital, Ecosystem, AI, Team, Cord, Disease, Pharmaceutical industry, Medical device, Datavant

SAN DIEGO, Sept. 20, 2023 /PRNewswire-PRWeb/ -- The rare patient advocacy organization Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.

Key Points: 
  • Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.
  • The Xcelerate RARE Challenge brought together academic and industry researchers and data scientists to use patient-reported data for rare pediatric neurodevelopmental diseases to address unanswered research questions about rare diseases.
  • SAN DIEGO, Sept. 20, 2023 /PRNewswire-PRWeb/ -- The rare patient advocacy organization Global Genes today announced the winners of its inaugural Xcelerate RARE Challenge Open Science Data Challenge at the RARE Advocacy Summit in San Diego.
  • The Xcelerate RARE Challenge, which was focused on rare pediatric neurodevelopmental diseases, brought together academic and industry researchers and data scientists to use patient-reported data to address unanswered research questions about rare diseases.